The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.
@article{Comenzo2001TheTO,
title={The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.},
author={Raymond L. Comenzo and Y Zhang and Carmen Mart{\'i}nez and Keren Osman and Guillermo A Herrera},
journal={Blood},
year={2001},
volume={98 3},
pages={
714-20
}
}Primary systemic amyloidosis (AL) is a protein conformation disorder in which monoclonal immunoglobulin light chains produced by clonal plasma cells are deposited as amyloid in the kidneys, heart, liver, or other organs. Why patients with AL present with amyloid disease that displays such organ tropism is unknown. This study tested the hypothesis that both the light-chain variable region (Ig V(L)) germ line genes used by AL clones and the plasma cell burden influenced AL organ tropism. To…
240 Citations
Analysis of Vλ-Jλ expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r(λIII) as a new amyloid-associated germline gene segment
- Biology
- 2002
It is demonstrated that Vλ-Jλ expression is more restricted in plasma cells from amyloidosis than from polyclonal bone marrow and overusage of just 2 gene segments can account for the λ light-chain overrepresentation typical of this disorder.
Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).
- Medicine, BiologyBlood
- 2003
Light chain-associated amyloidosis (AL) is a plasma cell dyscrasia in which the secreted monoclonal immunoglobulin (Ig) light chains form amyloid fibrils. There is considerable heterogeneity in…
Kidney Involvement in Light Chain Amyloidosis
- Medicine, Biology
- 2017
Refined diagnostic and staging systems based on biomarkers have helped in assessing prognoses and evaluating responses to therapy, which has considerably improved the management of systemic amyloidoses and created a favorable environment for a long-awaited improvement in the treatment of this disease.
Managing systemic light-chain amyloidosis.
- Medicine, BiologyJournal of the National Comprehensive Cancer Network : JNCCN
- 2007
For patients with limited organ involvement, intravenous melphalan in doses from 100 to 200 mg/m2 with autologous stem cell support (SCT) is an effective approach and, when followed at 3 months post-SCT with adjuvant thalidomide and dexamethasone for persistent plasma cell disease, has a 1-year hematologic response rate of 77%.
The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44.
- BiologyBlood
- 2012
The repertoire of variable region germline genes of λ LC preferentially targeting the heart was characterized and a single gene, IGVL1-44, was found associated with a 5-fold increase in the odds of dominant heart involvement (after adjusting for confounders in a multivariable logistic model).
Treating primary systemic amyloidosis with stem cell transplantation: outcomes in renal amyloidosis
- Medicine, Biology
- 2003
The concept of stem cell transplantation is discussed and some of the toxicities associated with its use are described and the significant contribution that immunoglobulin light chain variable region germline gene use makes to the organ tropism of primary systemic amyloidosis will be described.
The challenge of systemic immunoglobulin light-chain amyloidosis (Al).
- Biology, MedicineSub-cellular biochemistry
- 2012
Progress in therapy has helped many patients with AL achieve complete hematologic responses and significant reversal of organ damage but these benefits do not extend to that 10-15 % who present with advanced cardiac involvement.
Analysis of the complete lambda light chain germline usage in patients with AL amyloidosis and dominant heart or kidney involvement
- Medicine, BiologyPloS one
- 2022
An overview of I GLV-IGLJ and IGLC germline utilization in 85 patients classified in three clinically important subgroups with dominant cardiac, renal as well as cardiac and renal involvement found that IGLV3 was the most frequently detected IGLVs-family in patients with dominant heart involvement, whereas in renal patients IGLv1 were most frequently identified.
How we treat systemic light-chain amyloidosis.
- Medicine, BiologyClinical advances in hematology & oncology : H&O
- 2015
Physicians and clinical staff should be aware of the importance of providing best supportive care to patients with advanced AL-related organ dysfunction, given the patients' often tenuous hemodynamics and fragile functional status.
References
SHOWING 1-10 OF 49 REFERENCES
Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid‐related organ involvement and survival after stem cell transplantation
- Medicine, BiologyBritish journal of haematology
- 1999
There are important associations in AL amyloidosis among Ig VL gene utilization, organ‐system tropism and post‐SCT survival, and these findings indicate that there are important associated with immunoglublin light chain variable region (Ig VL) germline gene utilization.
Evidence that amyloidogenic light chains undergo antigen-driven selection.
- BiologyBlood
- 1998
Analysis of the nature and distribution of somatic mutations in amyloid V regions showed that there was statistical evidence of antigen selection in 8 of 14 clones, indicating that a substantial proportion of the amyloids clones developed from B cells selected for improved antigen binding properties and that pathogenic light chains show evidence of this selection.
Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients.
- Medicine, BiologyBlood
- 1998
Dose-intensive therapy should currently be considered as the preferred therapy for patients with AL amyloidosis who meet functional criteria for autologous transplantation, and the improvement in the median performance status of the 17 survivors at follow-up is statistically significant versus baseline.
The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients.
- Medicine, BiologyHaematologica
- 1999
This study investigated whether the degree of PC infiltration (PC%) and clonality (PC isotype ratio) affected survival in 56 consecutive patients with primary amyloidosis and demonstrated a powerful independent prognostic value at multivariate analysis.
Specificity of abnormal assembly in immunoglobulin light chain deposition disease and amyloidosis.
- BiologyJournal of molecular biology
- 1996
The D82I aggregate is dramatically different in morphology from aggregates obtained from amyloid-associated mutants, suggesting that specific amino acid residue changes can control not only the onset of aggregation disease but also aggregate morphology and disease type.
Cardiac immunocyte-derived (AL) amyloidosis: an endomyocardial biopsy study in 11 patients.
- Medicine, BiologyAmerican heart journal
- 1995
Light chain cardiomyopathy. Structural analysis of the light chain tissue deposits.
- BiologyThe American journal of pathology
- 1996
The diffuse binding to basement membranes and the high isoelectric point of the MCM kappa-light chain suggest electrostatic interaction as a possible mechanism of tissue deposition.
Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo.
- Medicine, BiologyUltrastructural pathology
- 1999
These findings substantiate the morphologic alterations observed in renal biopsy specimens and in the in vitro model and delineate the LC interactions with putative receptors at the mesangial cell surface that regulate mesangia cell pathobiologic responses and mesangian matrix homeostasis.
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.
- Medicine, BiologyThe New England journal of medicine
- 1997
Therapy with melphalan and prednisone results in objective responses and prolonged survival as compared with colchicine in patients with primary amyloidosis.






